Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
PTC Therapeutics
ClinicalTrials.gov Identifier:
NCT01557400
First received: March 15, 2012
Last updated: November 12, 2013
Last verified: November 2013
  Purpose

Duchenne/Becker muscular dystrophy (DBMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of DBMD in approximately 10-15% of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is an open-label trial for patients with nonsense mutation dystrophinopathy who received ataluren in a prior PTC-sponsored study at a clinical trial site in Europe, Israel, Australia, or Canada. The primary objective of the study is to evaluate the long-term safety of ataluren, as determined by adverse events and laboratory abnormalities.


Condition Intervention Phase
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Dystrophinopathy
Drug: Ataluren
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

Resource links provided by NLM:


Further study details as provided by PTC Therapeutics:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
    The safety profile of ataluren will be characterized by type, frequency, severity, timing, and relationship to ataluren of any adverse events or laboratory abnormalities


Secondary Outcome Measures:
  • Change from baseline in 6MWD as measured by the 6MWT (in ambulatory patients) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in subject and parent/caregiver-reported activities of daily living, as measured by the Egen Klassifikation (EK) scale (in nonambulatory patients) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in timed function tests (in ambulatory patients) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in pulmonary function as measured by spirometry (in nonambulatory patients) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in physical function as measured by the North Star Ambulatory Assessment (in ambulatory patients) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Changes in patient and/or parent/caregiver reports of disease status as measured by a standardized survey administered by site personnel [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 96
Study Start Date: May 2012
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ataluren
Ataluren
Drug: Ataluren
Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
Other Name: PTC124

Detailed Description:

The study will enroll boys with nonsense mutation DBMD who have a history of exposure to ataluren in a prior PTC study in nmDBMD (PTC124-GD-004-DMD, PTC124-GD-004e-DMD, PTC124-GD-007-DMD, PTC124-GD-007e, and PTC124-GD-008-DMD) at a trial site in Europe, Israel, Australia, or Canada. Patients will receive study drug 3 times per day (at breakfast, lunch, and dinner). Study assessments will be performed at clinic visits during screening and every 12 weeks during the 96-week treatment period. Patients must also return to the clinic for a post-treatment visit 6 weeks after the last dose of ataluren.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial
  • History of exposure to ataluren in a prior PTC study in nmDBMD
  • Male sex
  • Confirmed screening laboratory values within the specified ranges
  • In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during ataluren administration and the 6-week follow up period
  • Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, laboratory tests, and study restrictions

Exclusion Criteria:

  • Exposure to another investigational drug within 1 month prior to start of study treatment
  • Eligibility for another ataluren clinical trial that is actively enrolling study participants
  • Known hypersensitivity to any of the ingredients or excipients of study drug
  • Ongoing use of the following medications: coumarin based anti-coagulants, phenytoin, tolbutamide, paclitaxel, or systemic aminoglycoside therapy
  • Ongoing uncontrolled medical/surgical condition, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the patient or make it unlikely that follow-up would be completed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01557400

Locations
Australia
Royal Children's Hospital
Parkville, Victoria, Australia
Institute For Neuromuscular Research, The Children's Hospital at Westmead
Westmead, Australia
Belgium
University Hospital KU Leuven
Leuven, Belgium
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada
Canada, British Columbia
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Canada, Ontario
Children's Hospital of Western Ontario
London, Ontario, Canada
France
Hôpital d'Enfants CHU Timone
Marseille, France
Laboratoire d'Exploration Fonctionnelles
Nantes, France
Groupe Hospitalier La Pitie-Salpetriere
Paris, France
Germany
University of Essen - Clinic for Children
Essen, Germany
University Hospital
Freiburg, Germany
Israel
Hadassah Medical Center, Hebrew University Hospital
Jerusalem, Israel
Italy
Ospedale Maggiore Policlinico in Milan
Milan, Italy
Ospedale Pediatrico Bambino Gesu
Rome, Italy
U.O. Complessa di Neuropsichiatria Infantile
Rome, Italy
Spain
Hospital Sant Joan de déu
Barcelona, Spain
Hospital Universitari La Fe
Valencia, Spain
Sweden
Queen Silvia Children's Hospital
Goteburg, Sweden
Astrid Lindgren Pediatric Hospital
Stockholm, Sweden
United Kingdom
Great Ormond Street Hospital
London, United Kingdom
University of Newcastle Institute of Human Genetics
Newcastle Upon Tyne, United Kingdom
Sponsors and Collaborators
PTC Therapeutics
Investigators
Study Director: Jay Barth, MD PTC Therapeutics
  More Information

Publications:
Responsible Party: PTC Therapeutics
ClinicalTrials.gov Identifier: NCT01557400     History of Changes
Other Study ID Numbers: PTC124-GD-019-DMD
Study First Received: March 15, 2012
Last Updated: November 12, 2013
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Belgium: Federal Agency for Medicinal Products and Health Products
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Italy: The Italian Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Australia: Department of Health and Ageing Therapeutic Goods Administration
Sweden: Medical Products Agency
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Israel: Ministry of Health
Canada: Health Canada

Keywords provided by PTC Therapeutics:
Duchenne muscular dystrophy
Becker muscular dystrophy
Nonsense mutation
Premature stop codon
DMD
BMD
nmDBMD
DBMD
Ataluren
PTC124

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Muscular Diseases
Muscular Disorders, Atrophic
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases

ClinicalTrials.gov processed this record on October 29, 2014